Blog

- Uncategorized

Novel method combines heart biopsy and device implantation to reduce risk of complications

Endomyocardial biopsy (EMB) is a valuable method for diagnosing a range of cardiac conditions, but there is a risk of complications due to its invasive nature. Researchers have now found a way to combine right ventricular (RV) septal EMB, exploiting the benefit of 3D curved conduction system pacing (CSP) sheaths, with subsequent cardiac implantable electronic device (CIED, devices like pacemakers or defibrillators to regulate heart rhythm) implantation, using the same sheath.

Read More »

Atreon Orthopedics Announces FDA 510(k) Clearance and Full Market Launch of BioCharge® Autobiologic Matrix for Rotator Cuff Repair

DUBLIN, Ohio, Feb. 20, 2025 /PRNewswire/ — Atreon Orthopedics, LLC, a Columbus based innovator in tissue healing and regenerative technologies, announces the 510(k) clearance from the Food and Drug Administration (FDA) and the full market launch of BioCharge® Autobiologic Matrix, a bioresorbable synthetic implant designed to address biological failure modes in rotator cuff repair while improving repair integrity and long-term patient outcomes.

Read More »

Researchers describe new molecular mechanisms linked to insulin resistance

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to facilitate the uptake of glucose through tissues and organs, leading to an increase in blood glucose (chronic hyperglycemia). Since skeletal muscle is the tissue that uses the most glucose in response to insulin action, it is the most affected tissue by insulin resistance.

Read More »

CathVision Receives CE Mark for ECGenius System, Advancing Cardiac Monitoring and Analytics Technology in Europe

COPENHAGEN, Denmark, Feb. 19, 2025 /PRNewswire/ — CathVision, a medical technology company developing advanced electrophysiology solutions, is proud to announce that it has received CE Mark for its breakthrough product, ECGenius System. This regulatory milestone allows CathVision to market and distribute ECGenius System across the European Economic Area (EEA), bringing state-of-the-art electrophysiology solutions to healthcare providers and patients.

Read More »